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Abstract
Breast cancer remains the leading cause of cancer death in women owing to metastasis and the development of resistance to
established therapies. Macrophages are the most abundant immune cells in the breast tumor microenvironment and can both
inhibit and support cancer progression. Thus, gaining a better understanding of how macrophages support cancer could lead
to the development of more effective therapies. In this study, we ﬁnd that breast cancer-associated macrophages express high
levels of insulin-like growth factors 1 and 2 (IGFs) and are the main source of IGFs within both primary and metastatic
tumors. In total, 75% of breast cancer patients show activation of insulin/IGF-1 receptor signaling and this correlates with
increased macrophage inﬁltration and advanced tumor stage. In patients with invasive breast cancer, activation of Insulin/
IGF-1 receptors increased to 87%. Blocking IGF in combination with paclitaxel, a chemotherapeutic agent commonly used
to treat breast cancer, showed a signiﬁcant reduction in tumor cell proliferation and lung metastasis in pre-clinical breast
cancer models compared to paclitaxel monotherapy. Our ﬁndings provide the rationale for further developing the
combination of paclitaxel with IGF blockers for the treatment of invasive breast cancer, and Insulin/IGF1R activation and
IGF+ stroma cells as potential biomarker candidates for further evaluation.
Introduction
Breast cancer is the leading cause of cancer death in females
worldwide, and is characterized by a high proliferation rate,
an increased capacity to metastasize, and its ability to resist
standard therapies [1]. Triple-negative breast cancer
(TNBC) is a highly metastatic subtype of breast cancer that
accounts for ~ 20% of all breast cancer cases and has lim-
ited efﬁcacious treatment options [2]. Current standard
treatments for metastatic disease include radiotherapy and
chemotherapy [3, 4]. TNBC has a poorer survival rate, its
biology is comparatively less well-understood and currently
no effective speciﬁc targeted therapy is readily available [5].
Breast cancer has a propensity to give rise to distant
metastasis at sites such as the lungs, bone, and brain, which
can present up to 10 years after treatment [6]. Patients with
metastatic breast cancer ultimately often become resistant to
current chemotherapy treatments and as a result account for
>90% of breast cancer deaths [7], highlighting the need for
new therapeutic targets to treat metastatic burden more
effectively.
Tumor progression and response to therapy is not only
dependent on tumor intrinsic mechanisms but also involves
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modulation by surrounding non-malignant stromal cells in
the tumor microenvironment [8, 9]. Macrophages are the
most abundant leukocytes in the breast tumor
microenvironment [10] and an increase in tumor-associated
macrophages (TAMs) correlates with a poorer prognosis in
patients [11–13]. Macrophages can be polarized into M1-
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like anti-tumorigenic macrophages and M2-like pro-
tumorigenic macrophages [14–16]. M2-like macrophages
can inﬂuence tumor initiation, progression, metastasis [17–
19], and resistance to therapies [20–22].
Cancer progression relies on the continued propagation
of cancer cells, which can be stimulated by external ligands
activating signaling pathways of tumor cell survival and
proliferation, even when challenged with chemotherapy
[23–26]. The insulin-like growth factor (IGF) signaling axis
has been implicated in promoting cancer progression in
several tumor types including breast cancer [27–29], and in
breast cancer resistance to estrogen and HER2 receptor
inhibition [27, 30–32]. Interestingly, Fagan et al. [33]
showed that tamoxifen-resistant ER+ cells showed a
reduction in the number of IGF-1 receptors, whereas the
number of insulin receptors and AKT phosphorylation
levels remained unaltered when stimulated with Insulin and
IGF-2, suggesting that both IGF-1 and IGF-2 signaling may
support resistance of breast cancer cells to therapies.
However, the role of IGF signaling in tumor progression
and resistance to chemotherapy in breast cancer is not
completely understood yet [32]. We and others have
recently shown that stroma-derived IGFs promote survival
of cancer cells leading to therapy resistance in pancreatic
and brain cancer models, respectively [22, 34]. In the cur-
rent studies, we aimed to investigate the role of stroma-
derived IGF in breast cancer progression and metastasis,
and to explore the therapeutic opportunity of blocking IGF
signaling in combination with chemotherapy for the treat-
ment of breast cancer.
Results
Insulin and IGF-1 receptors are activated on tumor
cells in biopsies from breast cancer patients, and
this positively correlates with increased TAM
inﬁltration and advanced tumor stage
Macrophages have an important role in breast cancer pro-
gression and metastasis [35, 36] and have been shown to
express high levels of IGFs in other cancer types [22, 34],
but the role of IGF-expressing macrophages in breast cancer
has not yet been explored. To investigate whether IGF-
signaling pathways are activated in invasive breast cancer
progression and whether their activation correlates with
macrophage inﬁltration, we ﬁrst evaluated the activation
status of insulin and IGF-1 receptors in biopsies from breast
cancer patients, and the levels of inﬁltrated TAMs. Immu-
nohistochemical staining of serial sections of non-malignant
breast tissue (Fig. 1a) and breast cancer patients’ tissues
(Fig. 1b, c) revealed an increase in phospho-insulin/IGF-1
receptor levels in the breast cancer tissues along with
increased inﬁltration of CD68+ (pan-myeloid/macrophage
marker) and CD163+ (marker commonly used to identify
pro-tumorigenic M2-like macrophages) macrophages (Fig.
1a–d). Analysis of a tissue microarray (TMA) containing
samples from 75 breast cancer patients, with different tumor
stages but unspeciﬁed subtype, showed that Insulin/IGF-1R
signaling was activated in 56 of 75 (~ 75%) patients (Fig. 1e
and Supplementary Table. S1). Activation of insulin/IGF-1
receptors positively correlates with increased inﬁltration of
CD163+ macrophages in the tumor (Fig. 1f) and with
advanced tumor stage (Fig.1g).
87% of patients with invasive breast cancer have
insulin/IGF-1 receptors activated
As insulin/IGF-1 receptors activation positively correlates
with advanced tumor stage, we further analyzed biopsies
from patients with invasive breast cancer. Immunohisto-
chemical staining revealed that invasive breast cancer also
shows increased phospho-insulin/IGF-1 receptor levels in
tumor cells surrounded by CD163+ macrophages (Fig. 2a).
Analysis of a TMA containing 90 samples from patients
with invasive breast cancer showed that 78 of 90 (~ 87%) of
these patients have Insulin/IGF1 receptors activated (Fig.
2b, upper pie diagram, and Supplementary Table S2).
Among these 90 samples, 51 were TNBC of which 45 (~
88.2%) showed activation of Insulin/IGF1 receptors (Fig.
2b, lower, left pie diagram), 13 were hormone-receptor
positive (HR+) of which 12 (~ 92%) showed activation of
Insulin/IGF1 receptors (Fig. 2b, lower, middle pie diagram),
and 19 were HER2 positive (HER2+) of which 16 (~ 84%)
Fig. 1 75% of breast cancer patients have activated Insulin/IGF1
receptors and Insulin/IGF-1 receptor activation positively correlates
with macrophage inﬁltration and advanced tumor stage. a Serial sec-
tions of biopsies from non-malignant breast tissue immunohisto-
chemically stained for phospho-Insulin/IGF1 receptor, CD163 and
CD68. Scale bars, 100 μm and 50 μm. b and c Serial sections of
biopsies from breast cancer patients immunohistochemically stained
for phospho-insulin/IGF1 receptor, CD163, and CD68. Scale bars,
100 μm and 50 μm. d Bar graph depicting the quantiﬁcation of CD68
and CD163 positive macrophages in non-malignant breast tissue and
breast cancer tissue samples. Error bars represent s.d. (n= 3); * two-
tailed p-value ≤ 0.05, *** two-tailed p-value ≤ 0.005 using a student’s
t-test. e Pie diagram representing the percentage of phospho-Insulin/
IGF-1 receptor positive (red) and negative (green) tumors assessed in a
tissue microarray containing biopsies from 75 breast cancer patients. f
Contingency table and results from statistical analysis showing a
positive correlation between phospho-Insulin/IGF-1 receptor expres-
sion in breast tumors and increased CD163+ macrophage inﬁltration.
Chi-square= 4.37; p= 0.04. g Contingency table and results from
statistical analysis showing a positive correlation between phospho-
Insulin/IGF1 receptor and CD163+ macrophages co-expression and
tumor stage. Chi-square= 4.89; p= 0.03
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Fig. 2 Eighty-seven percent of patients with invasive breast cancer
have activated Insulin/IGF1 receptors. a Immunohistochemical stain-
ing of invasive breast cancer tissue serial sections stained for phospho-
Insulin/IGF1 receptor and CD163. Scale bars, 100 μm and 50 μm. b
Upper diagram: Pie diagram representing the percentage of phospho-
Insulin/IGF1 receptor positive (red) and negative (green) tumors
assessed in tissue microarray (TMA) containing biopsies from 90
consented patients with invasive breast cancer. Lower diagrams:
represent the percentage of phospho-Insulin/IGF1 receptor positive
(red) and negative (green) tumors of the molecular subsets, TNBC, HR
+, and HER2+. c Expression levels of Igf-1, Igf-2, cd163, and mrc1
associated with survival in breast cancer patients
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showed activation of Insulin/IGF1 receptors (Fig. 2b, lower,
right pie diagram). Using the cancer genome atlas database
we also found that increased gene expression of Igf-1, Igf-2,
and the M2-like macrophage markers cd163 and mrc1
positively correlates with reduced survival in breast cancer
patients (Fig. 2c). Together these results suggest an
important role for IGF signaling in invasive breast cancer of
all subtypes, including TNBC.
TAMs and ﬁbroblasts are the main sources of IGF-1
and IGF-2 in invasive breast cancer
To further understand the correlation between activation of
Insulin/IGF1 receptors and increased TAMs inﬁltration, we
used an orthotopic syngeneic TNBC pre-clinical model,
which has been shown to recapitulate the human disease
progression [37]. In brief, we isolated murine breast cancer
cells (Py230) from the genetically engineered spontaneous
breast cancer model MMTV-PyMT and transduced isolated
cells with a reporter lentivirus expressing zsGreen/luciferase
allowing in vivo imaging of tumor burden. To induce breast
tumor burden, Py230zsGreen/luciferase cells were orthoto-
pically implanted into the mammary fatpad of isogenic
immunocompetent recipient mice. Forty-two days after
implantation, primary tumors were surgically removed and
tumor tissue sections were analyzed by immunoﬂuorescent
and immunohistochemical staining. We found that tumors
were highly inﬁltrated by macrophages (F4/80+, CD68+,
CD206+) that surround proliferating tumor cells (Ki67+)
(Fig. 3a), which also express phosphorylated/activated
insulin/IGF-1 receptors (Fig. 3b). Thus, similar to what we
observed in human biopsies, murine breast cancer cells,
which are spatially located in close proximity to M2-like
TAMs, have activated Insulin/IGF-1 receptors.
Next, we aimed to identify the source of insulin and IGF-
1 receptors ligands, namely IGF-1 and IGF-2, in the tumor
microenvironment. Therefore, we enzymatically digested
primary tumors to prepare single cells suspensions and
isolated tumor cells, non-immune stromal cells and mac-
rophages, by ﬂow cytometry cell sorting (Supplementary
Fig. S1A B). Gene expression analysis of isolated cell
populations revealed that TAMs are the main source of Igf-
1 and that both TAMs and cancer-associated ﬁbroblasts
(CAFs) are major sources of Igf-2 in the breast tumor
microenvironment (Fig. 3c, d). Immunoﬂuorescent staining
of αSMA and Ki67 in the murine breast tumors showed that
αSMA+ stromal cells, which appear to be a major source of
IGF-2, also surround actively dividing tumor cells (Fig. 3e).
IGF-1 and IGF-2 are also expressed in the stroma sur-
rounding cancer cells in human TNBC samples (Supple-
mentary Fig. S2A), and gene expression analysis of Igf-1
and Igf-2 in human MDA-MB-231 TNBC cells and primary
human macrophages revealed that human macrophages
express high levels of Igf-1 and Igf-2, whereas there was
very little expression of these ligands in the breast cancer
cells (Supplementary Fig. S2B and C).
Metastasis-associated macrophages and ﬁbroblasts
remain the main sources of IGF-1 and IGF-2 in
pulmonary metastatic lesions
Breast cancer is a highly invasive disease and often
metastasizes to the lung. Orthotopically implanted Py230
breast cancer cells into syngeneic recipient mice effectively
metastasized to the lung, where they formed metastatic
tumors (Fig. 4a). We wondered whether IGF-1 and IGF-2
might also be expressed in the metastatic tumor micro-
environment and thereby provide a survival/proliferative
signal to disseminated cancer cells. To address this ques-
tion, we analyzed metastatic lung tumors from our animal
model for the expression of Igf-1 and Igf-2 in the metastasis-
associated stromal cells.
Metastatic tumors in lungs were ﬁrst conﬁrmed by bio-
luminescence ex vivo imaging and by hematoxylin and
eosin (H&E) staining (Fig. 4a). Immunoﬂuorescent staining
showed that pulmonary metastatic lesions are surrounded
by macrophages (F4/80+) and myoﬁbroblasts (αSMA+)
(Fig. 4b). Similar to what we observe at the primary site,
metastasis-associated macrophages and ﬁbroblasts express
high levels of Igf-1 and Igf-2, whereas disseminated breast
cancer cells do not express these ligands (Fig. 4c, d).
Together, these ﬁndings provide evidence that macrophages
and ﬁbroblasts are the main sources of IGF-1 and IGF-2
both at the primary and the metastatic site in invasive breast
cancer.
Fig. 3 TAMs and CAFs are the main sources of IGF-1 and IGF-2 in
invasive breast adenocarcinomas. a PY230 tumor cells were sub-
cutaneously implanted into the third mammary gland of syngeneic
recipient mice. Images show immunoﬂuorescent staining for F4/80
(green), Ki67 (red), and nuclei (blue) in murine breast cancer tissue
harvested at day 42 after tumor implantation. Scale bar 50 μm. b Serial
sections of immunohistochemical staining for CD68, CD206 and
phospho-Insulin/IGF1 receptor in murine breast tumors. Scale bar
50 μm. c Igf-1 mRNA expression levels were quantiﬁed in tumor cells,
non-immune stromal cells and tumor-associated macrophages isolated
from murine breast cancer tumors by ﬂow cytometry. Error bars
represent s.e. (n= 3), * p-value ≤ 0.05 using one-way ANOVA and
Bonferroni post hoc test. d Igf-2 mRNA expression levels were
quantiﬁed in tumor cells, non-immune stromal cells and tumor-
associated macrophages isolated from murine breast cancer tumors by
ﬂow cytometry. Error bars represent s.e. (n= 3), * p-value ≤ 0.05
using one-way ANOVA and Bonferroni post hoc test. e Immuno-
ﬂuorescent images of αSMA (green), Ki67 (red), and nuclei (blue) in
breast tumors. Scale bar 50 μm
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Fig. 4 Metastasis-associated macrophages and ﬁbroblasts express IGF-
1 and IGF-2 in metastatic lungs. a Left, identiﬁcation of metastatic
tumor lesions in the lung by bioluminescent imaging technique of
orthotopically implanted PY230luc breast cancer cells. Right, images
show H&E staining of metastatic foci in the lungs. Arrows indicate
metastatic foci, scale bars 200 μm, 100μm, and 50 μm. b Immuno-
ﬂuorescent images of lung metastatic foci stained for F4/80 (green),
αSMA (green), Ki67 (red), and nuclei (blue). Scale bar 50 μm. c
Quantiﬁcation of Igf-1 mRNA expression levels in metastatic tumor
cells, metastasis-associated non-immune stromal cells and metastasis-
associated macrophages isolated from pulmonary metastasis. Error
bars represent s.e. (n= 3), * p-value ≤ 0.05, *** p-value ≤ 0.0001
using one-way ANOVA and Bonferroni post hoc test. d) Quantiﬁca-
tion of Igf-2 mRNA expression levels in metastatic tumor cells,
metastasis-associated non-immune stromal cells and metastasis-
associated macrophages isolated from pulmonary metastasis. Error
bars represent s.e. (n= 3), *** p-value ≤ 0.05 using one-way ANOVA
and Bonferroni post hoc test
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Combination treatment of invasive breast cancer
with paclitaxel and IGF blocking antibody reduces
tumor cell proliferation and metastasis in a
syngeneic orthotopic Py230 model
To determine whether IGF signaling affects breast cancer
progression, metastasis and response to paclitaxel, a stan-
dard chemotherapeutic agent used to treat breast cancer, we
treated mice orthotopically implanted with Py230 TNBC
cells, with control IgG antibody, IGF-1/2 blocking antibody
xentuzumab, paclitaxel, or xentuzumab with paclitaxel (Fig.
5a). As expected, control and paclitaxel treated mice
showed high levels of insulin and IGF-1 receptor activation
in the primary breast cancer tumors, whereas the xentuzu-
mab and xentuzumab with paclitaxel treated groups showed
markedly reduced levels of insulin and IGF-1 receptor
activation, conﬁrming that xentuzumab has reached the
tumor and has blocked IGF signaling (Fig. 5b) [38]. No
differences were seen in primary tumor growth (Supple-
mentary Fig. S3A), in tumor cell death (Supplementary Fig.
S3B) or in TAM inﬁltration of primary tumors (Supple-
mentary Fig. S3C) between the different treatment groups.
However, control IgG-treated mice showed higher levels of
Ki67+ proliferating tumor cells, which were modestly
reduced by both paclitaxel and xentuzumab single treat-
ments and signiﬁcantly reduced by the combination
treatment of xentuzumab with paclitaxel (Fig. 5c, d). In
addition, mice treated with the combination of xentuzumab
with paclitaxel treatment showed a reduction in lung
metastasis incidence (Fig. 5e). Although there were no
signiﬁcant differences in the number of metastatic foci in
the different treatment groups (Fig. 5f), we found a sig-
niﬁcant reduction in the size of metastatic lesions and
overall lung metastatic burden in the group treated with
both paclitaxel and xentuzumab (Fig. 5g–i). These data
suggest that initial metastatic seeding is not affected by the
combination treatment, but that paclitaxel/xentuzumab
treatment impairs metastatic outgrowth of disseminated
breast cancer cells.
Combination treatment of invasive breast cancer
with paclitaxel and IGF blocking antibody reduces
tumor cell proliferation and metastasis in a
syngeneic orthotopic 4T1 model
To conﬁrm the results from the Py230 experiment in
another model, 4T1-zsGreen/luciferase cells were implanted
into the mammary fatpad of syngeneic Balb/c mice and
treated with isotype control antibody, paclitaxel, xentuzu-
mab, or paclitaxel with xentuzumab (Fig. 6a). In accordance
with our previous ﬁndings, insulin and IGF-1R receptor
activation was markedly reduced in the mice treated with
xentuzumab alone and paclitaxel with xentuzumab (Sup-
plementary Fig. S4A) [38]. In this model, we found that
primary tumor growth was signiﬁcantly reduced by pacli-
taxel treatment and even further reduced by the combination
treatment paclitaxel + xentuzumab (Fig. 6b). Analysis of
Ki67 + proliferating cells in the primary tumor showed a
signiﬁcant reduction in paclitaxel treated mice and reduced
further in paclitaxel with xentuzumab treated mice com-
pared with control IgG mice (Fig. 6c, d). The numbers of
lung metastatic foci were signiﬁcantly reduced by both
paclitaxel alone and the combination of paclitaxel + xen-
tuzumab compared with control treatment group (Fig. 6e).
However, only the combination treatment of paclitaxel +
xentuzumab signiﬁcantly reduced the average metastatic
lesion size and the overall metastatic burden (Fig. 6f–h).
Taken together, our ﬁndings indicate that IGF-1 and 2
are highly expressed by both macrophages and ﬁbroblasts in
invasive breast cancer, and that blockade of IGF potentiates
the efﬁcacy of paclitaxel (Fig. 6i).
Discussion
Here we show that IGF-1 and 2 are secreted by macro-
phages and ﬁbroblasts, both at the primary site and meta-
static site in invasive breast cancer, and that blocking IGF
increases the efﬁcacy of paclitaxel, a chemotherapeutic
Fig. 5 Combined treatment of IGF blocking antibody with paclitaxel
decreases breast cancer proliferation and metastasis in Py230 model. a
Py230 luciferase cells were orthotopically implanted into the third
mammary fatpad of syngeneic C57BL/6 recipient mice and mice were
treated, starting when tumors reached between 5–8 mm2, twice a week
i.p., with control IgG antibody, IGF blocking antibody xentuzumab
(100 mg/kg), paclitaxel (100 mg/kg), or a combination of xentuzumab
with paclitaxel (n= 8 mice per group). b Immunohistochemical
staining of phospho-insulin/IGF-1R in breast tumors treated with IgG
(control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale
bars 100 μm and 50 μm. c Immunoﬂuorescent staining of Ki67 in
primary tumors treated with IgG (control), paclitaxel, xentuzumab, or
paclitaxel + xentuzumab. Scale bar 50 μm. d Quantiﬁcation of Ki67-
positive tumor cells in tumors treated with IgG (control), paclitaxel,
xentuzumab or paclitaxel + xentuzumab. 3–5 ﬁelds counted/mouse
tumor, n= 3–4 mice per treatment group, * p ≤ 0.05 using one-way
ANOVA and Bonferroni post hoc test. e Percentage of mice presenting
with lung metastasis per treatment group. (n= 8 mice/group). f
Quantiﬁcation of number of lung metastatic foci per 100mm2 in mice
treated with control IgG, paclitaxel, xentuzumab, or paclitaxel +
xentuzumab. ns, non-signiﬁcant differences using one-way ANOVA
and Bonferroni post hoc test. g Average size of pulmonary metastatic
lesions (mm2) in mice treated with control IgG, paclitaxel, xentuzu-
mab, or paclitaxel + xentuzumab, * p ≤ 0.05, using one-way ANOVA
and Bonferroni post hoc test. h H&E staining of lung metastatic foci in
mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel +
xentuzumab. Scale bar 50 μm. i Total metastatic burden (mm2) in mice
treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with
xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post
hoc test
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agent commonly used for the treatment of invasive breast
cancer (Fig. 6i). Breast cancer, and in particular TNBC,
remains a highly metastatic and potentially lethal disease
with a need to identify additional speciﬁc molecular targets
and to develop more effective therapies [4, 5]. Although
IGF signaling has been shown to support progression of HR
+ and HER2+ breast cancer and the development of
resistance to established therapies, its precise role in TNBC
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remains elusive [32]. In our TNBC model, we found that
TAMs and CAFs secrete IGF-1 and 2 at both the primary
site and the pulmonary metastatic site. Zhang et al. [39],
previously reported that CAF-derived IGF-1 primes breast
cancer cells for bone metastasis. These studies both suggest
that stromal-derived IGF plays an important role in the
metastatic process of breast cancer.
In this study, we ﬁnd that the Insulin/IGF1R signaling
pathway is activated in 78 of 90 (~ 87%) of patients with
invasive breast cancer and in 45 of 51 (~ 88.2%) TNBC
patients, suggesting IGF may be a promising therapeutic
target for this highly aggressive breast cancer subtype. We
also observed that activation of Insulin/IGF1 receptor sig-
naling positively correlates with increased levels of mac-
rophage inﬁltration and advanced tumor stage in patients,
suggesting that Insulin/IGF1 receptor activation and/or
stroma expression of IGF could be predictive biomarker
candidates for further evaluation.
To investigate the therapeutic potential of blocking IGF
signaling in invasive breast cancer, we tested the IGF-1/2
blocking antibody xentuzumab (Boehringer Ingelheim) in
two pre-clinical mouse models of invasive TNBC breast
cancer, which metastasize to the lungs. In both models, we
ﬁnd that combining xentuzumab with paclitaxel results in
reduced incidence of metastasis, as well as a signiﬁcant
reduction of tumor cell proliferation and metastatic burden
compared with monotherapy. In agreement with our ﬁnd-
ings, Gooch et al. [40], previously showed that IGF-1
promotes proliferation of paclitaxel treated cells in vitro.
Interestingly, xentuzumab + paclitaxel combination treat-
ment signiﬁcantly decreases the size of metastatic lesions
but not the number of foci suggesting that the combination
treatment affects metastatic outgrowth rather than the
metastatic seeding.
IGF1R inhibitors have been assessed in clinical trials for
metastatic HR+ as well as TNBC but have shown limited
success [41–46]. Two promising IGF ligand blocking
antibodies, xentuzumab and MEDI-573, are currently being
evaluated in clinical trials in HR+ metastatic breast cancer
patients in combination with everolimus and exemestane
(NCT02123823) and in hormone sensitive metastatic breast
cancer in combination with letrozole (NCT01446159),
respectively. In contrast to IGF1R antibodies, IGF blocking
antibodies neutralize both ligands IGF-1 and IGF-2 and
thereby inhibit proliferative signaling through both Insulin
and IGF1 receptors without affecting insulin metabolic
signaling [38, 47].
Breast cancer cells survive poorly in isolation and par-
ticipate in a complex relationship with surrounding stromal
and immune cells in the tumor microenvironment, which
can support tumor cell survival, proliferation, and spreading
to other organs [17, 20, 21, 36, 39]. CAFs and TAMs are
the most abundant stromal cells in solid cancers, including
breast cancer. However, different populations of CAFs and
TAMs with both pro- and anti-tumorigenic functions co-
exist in tumors [48–50]. Therefore, therapies aiming to
speciﬁcally inhibit the tumor supporting functions of stro-
mal cells, without affecting their anti-tumorigenic functions,
may be more effective than ablation therapies in restraining
tumor progression [26, 51]. Our ﬁndings indicate that
blocking IGFs in combination with paclitaxel, decreases
tumor cell proliferation and breast cancer pulmonary
metastasis without affecting macrophage inﬁltration. In
conclusion, this study suggests that stroma-derived IGFs
support breast cancer metastasis and modulate its response
to paclitaxel, providing the rationale for further evaluation
of IGF blocking antibodies in combination with paclitaxel
in the treatment of invasive breast cancer.
Fig. 6 Combined IGF blocking antibody with paclitaxel decreases
metastatic burden in 4T1 breast cancer model. a 4T1-zsgreen/lucifer-
ase cells were orthotopically implanted into the third mammary fatpad
of syngeneic Balb/c recipient mice and were treated when tumors
reached ~ 5 mm mean diameter, over 2 weeks the mice received four
treatments by i.p. with control human IgG antibody (n= 8 mice), IGF
blocking antibody xentuzumab (100 mg/kg) (n= 8 mice), paclitaxel
(100 mg/kg) (n= 9 mice) or a combination of xentuzumab with
paclitaxel (n= 9 mice). b Graph showing tumor mean diameter (mm2)
measured by calipers before and during treatment with isotype control,
xentuzumab, paclitaxel, and paclitaxel with xentuzumab. Error bars
represent s.e. (IgG antibody and xentuzumab n= 8, paclitaxel and
paclitaxel with xentuzumab n= 9), * p-value ≤ 0.05, ** p-value ≤ 0.01
using two-way ANOVA and Bonferroni post hoc test. c Immuno-
ﬂuorescent staining of Ki67 in primary tumors treated with IgG
(control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale
bar 50 μm. d Quantiﬁcation of Ki67-positive tumor cells in tumors
treated with human IgG (control), paclitaxel, xentuzumab, or paclitaxel
+ xentuzumab. A total of 3–5 ﬁelds counted/mouse tumor, n= 8–9
mice per treatment group, ns, non-signiﬁcant differences, ** p ≤ 0.01,
*** ≤ 0.0001 p using one-way ANOVA and Bonferroni post hoc test.
Images quantiﬁed using NIS-Elements Advanced Research software. e
Quantiﬁcation of number of lung metastatic foci per 100mm2 in mice
treated with control IgG, paclitaxel, xentuzumab, or paclitaxel +
xentuzumab. Error bars represent s.e. (IgG antibody n= 7, paclitaxel
n= 9, xentuzumab n= 8, and paclitaxel with xentuzumab n= 9) ns,
non-signiﬁcant differences, * p-value ≤ 0.05, using one-way ANOVA
and Bonferroni post hoc test. f Average size of pulmonary metastatic
lesions (mm2) in mice treated with control IgG, paclitaxel, xentuzu-
mab, or paclitaxel + xentuzumab. Error bars represent s.e., ns, non-
signiﬁcant differences, ** p ≤ 0.01, using one-way ANOVA and
Bonferroni post hoc test. g H&E staining of lung metastatic foci in
mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel +
xentuzumab. Scale bar 50 μm. h Total metastatic burden (mm2) in
mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel
with xentuzumab. Error bars represent s.e., ns, non-signiﬁcant differ-
ences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc
test. i Schematics describing the role of stroma-derived IGF-1 and 2 in
regulating the response of metastatic breast cancer to paclitaxel
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Materials and methods
Generation of primary PyMT-derived breast cancer
cells
Py230 cells (hormone-receptor negative and HER2 low)
were generated in Ellies lab (University of California San
Diego, USA) and obtained from spontaneously arising
tumors in MMTV-PyMT C57Bl/6 female mice by serial
trypsinization and limiting dilution [52]. The mouse model
used for obtaining these tumors has been described in detail
previously [53, 54].
Generation of 4T1 derived breast cancer cells
4T1 cells were purchased from the ATCC and were ori-
ginally obtained from a spontaneously arising mammary
tumor in BALB/cfC3H mice [55, 56]. The orthotopic model
using these cells has been described in detail previously
[57].
Cell lines and culture conditions
Murine Py230 cells were cultured in DMEM/F-12 culture
media supplemented with 10% FBS and supplemented with
MITO serum extender (Corning #355006), 1% penicillin/
streptomycin at 37 °C, in a 5% CO2 incubator. Murine
4T1 cells were cultured in RPMI-1640 culture media sup-
plemented with 10% FBS, 1% penicillin/streptomycin at 37
°C, in a 5% CO2 incubator. Human MDA-MB231 breast
cancer cells were cultured in DMEM supplemented with
10% FBS, 1% penicillin/streptomycin, at 37 °C, 5% CO2
incubator. Cells were authenticated, and periodically tested
for mycoplasma contamination.
Generation of primary macrophages
Primary human macrophages were obtained from blood
samples of healthy volunteers. Magnetic bead afﬁnity
chromatography was performed to purify CD14+ mono-
cytes as per manufacturer’s instructions (Miltenyi Biotec,
Woking, UK). Monocytes were incubated in RPMI media
with 10% FBS and 50 ng/mL recombinant human M-CSF
(Peprotech, London, UK) for 5 days post puriﬁcation.
Syngeneic orthotopic breast cancer models
Two orthotopic syngeneic breast cancer models were used
in these studies. In the ﬁrst breast cancer model (Fig. 5),
2× 106 Py230 luciferase/zsGreen labeled cells were injec-
ted into the fatpad of the third mammary gland of C57BL/6
6–8 week-old female mice. In the second model (Fig. 6),
5× 105 4T1 luciferase/zsGreen labelled cells were injected
into the fatpad of the third mammary gland of BALB/c 6–8
week-old female mice. Tumors were measured with calipers
twice a week and treatment was started when tumors started
to grow and measured between 5 and 8 mm mean diameter.
Mice were administered i.p with IgG isotype control anti-
body, paclitaxel (100 mg/kg), IGF-1/2 blocking antibody
xentuzumab (100 mg/kg) [38] kindly provided by Boeh-
ringer Ingelheim, or Paclitaxel with xentuzumab, twice a
week for 15 days. At humane endpoint, primary tumors and
lungs were harvested, imaged using IVIS technology and
tissues were either digested for FACS sorting and analysis
(see details below) or formalin-ﬁxed and parafﬁn-
embedded. Parafﬁn-embedded lungs were serially sec-
tioned through the entire lung. Sections were stained with
H&E, and images were taken using a Zeiss Observer Z1
Microscope. Number of foci and total area of metastatic foci
were calculated to estimate seeding and metastasis burden
using ZEN imaging software.
FACS sorting and analysis of tumors
Tumor cells, TAMs, and stromal cells from murine primary
breast tumors and pulmonary metastasis were analyzed and
sorted using ﬂow cytometry (FACS ARIA II, BD
Bioscience, CA, USA). Single cell suspensions were pre-
pared as previously described [22]. Cells were stained with
Sytox blue viability marker (Life Technologies, Warring-
ton, UK) and conjugated antibodies against anti-CD45-PE/
Cy7 (Biolegend, Cambridge, UK, clone 30-F11) and anti-
F4/80-APC (Biolegend, clone BM8) and analyzed using
FACS Canto II (BD Biosciences).
Gene expression
Total RNA was isolated from FACS sorted tumor cells,
TAMs and stromal cells from primary breast tumors and
lung metastasis. RNA extraction and cDNA were performed
as previously described [22]. Gene-speciﬁc Qiagen Quan-
tiTect Assay primers were used for qPCR analysis and
relative expression levels were normalized to gapdh
expression using the formula < 2^− (Ct gene of interest −
Ct gapdh) [58].
Gene expression analysis in TCGA database
We analyzed the Cancer Genome Atlas (TCGA) data for
association between gene expression levels of Igf1, Igf2,
cd163, and mrc1 and 5-year overall survival. The R/Bio-
conductor package ‘TCGA2STAT’ (v1.2) [59] was used to
download the Illumina HiSeq RNAseqV2 mRNA expres-
sion and clinical data for 1097 Breast cancer samples from
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the TCGA data portal. The clinical data set was ﬁltered
down to contain only those breast cancer cases classiﬁed as
“inﬁltrating/invasive ductal carcinoma”, resulting in a
reduced data set of 879 patients. For each of the candidate
genes, we assessed two groups of patients; one consisting of
those expressing the gene in the top 10% of expression and
another containing patients expressing the gene in the bot-
tom 10%. We compared their survival using a log-rank test
at 5% signiﬁcance, using the ‘survival’ (v2.41-3) package
and plotted Kaplan–Meier curves for our ‘high’ and ‘low’
gene expression groups using ‘survminer’ (v0.4.0) within
the ‘TCGAbrowser’ (v0.1.0) toolkit, reporting the p-value
from the log-rank test (see Fig. 2c).
Tissue microarrays
A TMA containing 75 breast cancer samples from con-
sented patients was purchased from the Liverpool Tissue
Bank. This TMA did not provide information of cancer
subtypes. A second TMA BR10011 containing 90 invasive
breast cancer samples was purchased from US Biomax.
Among these 90 invasive breast cancer samples 51 were
TNBC, 13 were HR+, and 19 were HER2+. Both TMAs
were subjected to immunohistochemical staining and scor-
ing by a pathologist. Detailed information of both TMAs is
provided in Supplementary Tables S1 and S2.
Immunohistochemistry and immunoﬂuorescence
An automated DAKO PT-link (DAKO, Ely, UK) was used
for deparafﬁnization and antigen retrieval of parafﬁn-
embedded human and mouse breast tumors and lung
metastasis. Tissues were immuno-stained using the DAKO
envision + system-HRP.
Antibodies and procedure used for immunohistochemistry
All primary antibodies were incubated for 2 h at room
temperature diluted in DAKO envision kit antibody diluent:
Mouse CD68 (Abcam, Cambridge, UK, ab31630 used at
1:100 after low pH retrieval). Human CD68 (DAKO, clone
KP1, M081401-2), CD163 (Abcam, ab74604), Phospho-
Insulin/IGF-1R (R&D, Abingdon, UK, AF2507), phospho-
insulin receptor (Lifespan Biosciences, Nottingham, UK,
LS-C177981), phospho-IGF-1R (Biorbyt, Cambridge, UK,
orb97626), IGF-1 (Abcam, ab9572), IGF-2 (Abcam,
ab9574), CD206 (Abcam, ab8918), dilutions and conditions
used as previously described [22]. Subsequently, samples
were incubated with secondary HRP-conjugated antibody
(from DAKO envision kit) for 1 h at room temperature.
Staining was developed using diamino-benzidine and
counterstained with hematoxylin.
Antibodies and procedure used for Immunoﬂuorescence on
parafﬁn-embedded tissues
Tissue sections were incubated overnight at RT with the
following primary antibodies F4/80 (Biolegend, #123102
used at 1:200 after low pH antigen retrieval), Ki67 (Abcam
ab15580 used at 1:1000 after low pH antigen retrieval)
αSMA (Abcam ab7817 used at 1:100, after low pH antigen
retrieval). Samples were washed with PBS and incubated
with goat anti-rat 488 (Abcam ab96887), goat anti-rabbit
594 (Abcam ab98473) and goat anti mouse 488 (Abcam
ab98637) secondary antibodies respectively all used at
1:300 and DAPI at 1:600 for 2 h at RT. Slides were washed
with PBS, ﬁnal quick wash with distilled water and
mounted using DAKO ﬂuorescent mounting media.
Statistical methods
Statistical analysis for in vitro assays and animal studies
was performed using unpaired two-tailed Student's t-test or
one-way ANOVA coupled with Bonferroni’s post hoc tests,
and the GraphPad Prism 5 program. All error bars indicate
s.d. of n= 3 (in vitro studies) or SEM n= 3–9 (animal
studies). Human samples were analyzed using Fisher’s exact
test and the Matlab version 2006b program. For animal
studies the group size was calculated by power analysis
using a signiﬁcance level kept at 5% and the power at 80%
(according to approved corresponding Home Ofﬁce Project
License Application).
Institutional approvals
Human tissue studies adhered to national guidelines and
were approved by the University of Liverpool. Human
breast cancer tissues were either patient-consented excess
material obtained from the Liverpool Tissue Bank or pur-
chased from US Biomax. Mice were maintained under
speciﬁc pathogen-free conditions and experiments were
performed under an approved project licence (reference
number: 403725) as according to current UK legislation, at
the Biomedical Science Unit at the University of Liverpool.
Blood collection studies were approved by the National
Research Ethics (Research Integrity and Governance Ethics
committee- Reference: RETH000807). Informed consent
for blood donation was given from each volunteer based on
approved institutional protocols.
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